Fortrea Backs GE Healthcare’s New PET Tracer in Completed Phase 1 Study

Fortrea Holdings Inc. (FTRE) announced an update on their ongoing clinical study.

The study, officially titled “A Phase 1, Single-Center, Open-Label, Single-Arm, Dose-Escalation, Positron Emission Tomography Study…,” tests new imaging agents from GE Healthcare in healthy volunteers. It aims to check basic safety, how the drugs move in the body, and how well they support PET/CT scans, an early but key step before any patient use.

The treatment combines two agents, GEH200520 Injection and GEH200521 (18F) Injection. GEH200520 is given first, then GEH200521 (18F), with the goal of improving PET/CT image quality and mapping how the tracer spreads through the body.

The trial is an interventional Phase 1 study with no randomization and a single treatment path. It is open label, so everyone knows what is given, and there is no placebo group, with the main purpose to support future diagnostic use rather than treat disease.

Volunteers receive rising doses of GEH200520 while GEH200521 (18F) stays fixed, and then undergo repeated PET/CT scans. This stepwise design helps spot any dose-related safety issues and builds a basic profile of how the tracer behaves over time in normal tissue.

The study started enrolling in 2024, with each volunteer followed for about one month in part A and just over a month in part B. The primary work is now marked as completed, and the record was last updated on March 5, 2026, signaling the operational phase is done and data review is underway.

The “completed” status suggests GE Healthcare and partners, including Fortrea and PPD Development, have finished dosing and scanning. Investors should watch for when full results are posted, as positive safety data can support further trials and potential licensing or co-development deals.

For Fortrea (FTRE), a contract research player, this update confirms its role in complex imaging trials and can support the story of steady, service-based revenue. While the study itself won’t drive big upside, it reinforces Fortrea’s positioning in advanced diagnostics outsourcing, an area where demand is rising.

In the broader imaging market, GE Healthcare faces rivals like Siemens Healthineers and Philips in PET/CT solutions. A clean Phase 1 outcome for GEH200520/GEH200521 could strengthen GE’s pipeline narrative, which may indirectly support confidence in CRO partners such as Fortrea that execute these early-stage projects.

Overall, this completed Phase 1 PET study marks a modest but clear de-risking step for GE’s imaging agent program and a small credibility win for Fortrea’s early development services. The study has been completed and recently updated, with more details available on the ClinicalTrials portal.

To learn more about FTRE’s potential, visit the Fortrea Holdings Inc. drug pipeline page.